



**ASX & MEDIA RELEASE
4 APRIL, 2012**

CORRECTIVE ANNOUNCEMENT

In the announcement made by Novogen Limited on 22 February, 2012 it was noted that the announcement was dated 22 January, 2012 in error and should have been dated 22 February, 2012.

On 2 April, 2012 Novogen Limited announced an in specie dividend and referred to the prior announcement issued on 22 February, 2012 by the incorrect date, being the date contained on the announcement of 22 January, 2012. The correct date should have been 22 February, 2012 and not 22 January, 2012 as noted in the 2 April, 2012 announcement.

About Novogen Limited

Novogen Limited is an Australian biotechnology company based in Sydney, Australia. Novogen conducts research and development on oncology therapeutics through its subsidiary, Marshall Edwards, Inc., and is developing glucan technology through its subsidiary, Glycotex, Inc. More information on the Novogen group of companies can be found at www.novogen.com.

ISSUED FOR	:	NOVOGEN LIMITED
LISTINGS	:	ASX (CODE NRT), NASDAQ (CODE NVGN).
FOR FURTHER INFORMATION :	:	PETE DE SPAIN, SR DIRECTOR IR AND CORPORATE COMMUNICATIONS, MARSHALL EDWARDS, INC. TEL +1 858-792-3729 http://www.marshalledwardsinc.com
ISSUED BY CONTACT	:	WESTBROOK COMMUNICATIONS IAN WESTBROOK TEL (02) 9231 0922